These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 30299265)

  • 21. Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges.
    Jeanes YM; Reeves S
    Nutr Res Rev; 2017 Jun; 30(1):97-105. PubMed ID: 28222828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of sleep-disordered breathing on metabolic dysfunctions in patients with polycystic ovary syndrome.
    Chatterjee B; Suri J; Suri JC; Mittal P; Adhikari T
    Sleep Med; 2014 Dec; 15(12):1547-53. PubMed ID: 25311833
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathophysiology of polycystic ovary syndrome revisited: Current understanding and perspectives regarding future research.
    Harada M
    Reprod Med Biol; 2022; 21(1):e12487. PubMed ID: 36310656
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Chromium Supplementation on Element Distribution in a Mouse Model of Polycystic Ovary Syndrome.
    Chen TS; Chen YT; Liu CH; Sun CC; Mao FC
    Biol Trace Elem Res; 2015 Dec; 168(2):472-80. PubMed ID: 26041153
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Impact of Mineral Supplementation on Polycystic Ovarian Syndrome.
    ElObeid T; Awad MO; Ganji V; Moawad J
    Metabolites; 2022 Apr; 12(4):. PubMed ID: 35448525
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hyperandrogenic origins of polycystic ovary syndrome - implications for pathophysiology and therapy.
    Abbott DH; Dumesic DA; Levine JE
    Expert Rev Endocrinol Metab; 2019 Mar; 14(2):131-143. PubMed ID: 30767580
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polycystic Ovary Syndrome as a systemic disease with multiple molecular pathways: a narrative review.
    Carvalho LML; Dos Reis FM; Candido AL; Nunes FFC; Ferreira CN; Gomes KB
    Endocr Regul; 2018 Oct; 52(4):208-221. PubMed ID: 31517612
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nutritional management in women with polycystic ovary syndrome: A review study.
    Faghfoori Z; Fazelian S; Shadnoush M; Goodarzi R
    Diabetes Metab Syndr; 2017 Nov; 11 Suppl 1():S429-S432. PubMed ID: 28416368
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exploration of the Relationship Between Gut Microbiota and Polycystic Ovary Syndrome (PCOS): a Review.
    Zhao X; Jiang Y; Xi H; Chen L; Feng X
    Geburtshilfe Frauenheilkd; 2020 Feb; 80(2):161-171. PubMed ID: 32109968
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Genetic aspects of polycystic ovary syndrome].
    Jakubowski L
    Endokrynol Pol; 2005; 56(3):285-93. PubMed ID: 16350721
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The obesogen tributyltin induces features of polycystic ovary syndrome (PCOS): a review.
    Merlo E; Silva IV; Cardoso RC; Graceli JB
    J Toxicol Environ Health B Crit Rev; 2018; 21(3):181-206. PubMed ID: 30015594
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome.
    Abdalla MA; Deshmukh H; Atkin S; Sathyapalan T
    Ther Adv Endocrinol Metab; 2020; 11():2042018820938305. PubMed ID: 32670541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of vitamin D deficiency in Slovak women with polycystic ovary syndrome and its relation to metabolic and reproductive abnormalities.
    Figurová J; Dravecká I; Javorský M; Petríková J; Lazúrová I
    Wien Klin Wochenschr; 2016 Sep; 128(17-18):641-8. PubMed ID: 25787215
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nutrients as novel therapeutic approaches for metabolic disturbances in polycystic ovary syndrome.
    Mansour A; Hosseini S; Larijani B; Mohajeri-Tehrani MR
    EXCLI J; 2016; 15():551-564. PubMed ID: 28096785
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited.
    Rosenfield RL; Ehrmann DA
    Endocr Rev; 2016 Oct; 37(5):467-520. PubMed ID: 27459230
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Natural molecules for the therapy of hyperandrogenism and metabolic disorders in PCOS.
    Cappelli V; Musacchio MC; Bulfoni A; Morgante G; De Leo V
    Eur Rev Med Pharmacol Sci; 2017 Jun; 21(2 Suppl):15-29. PubMed ID: 28724177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adherence to the Mediterranean Diet, Dietary Patterns and Body Composition in Women with Polycystic Ovary Syndrome (PCOS).
    Barrea L; Arnone A; Annunziata G; Muscogiuri G; Laudisio D; Salzano C; Pugliese G; Colao A; Savastano S
    Nutrients; 2019 Sep; 11(10):. PubMed ID: 31547562
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characteristics of obesity in polycystic ovary syndrome: Etiology, treatment, and genetics.
    Glueck CJ; Goldenberg N
    Metabolism; 2019 Mar; 92():108-120. PubMed ID: 30445140
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment.
    Escobar-Morreale HF
    Nat Rev Endocrinol; 2018 May; 14(5):270-284. PubMed ID: 29569621
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nutritional supplements and herbal medicines for women with polycystic ovary syndrome; a systematic review and meta-analysis.
    Arentz S; Smith CA; Abbott J; Bensoussan A
    BMC Complement Altern Med; 2017 Nov; 17(1):500. PubMed ID: 29178904
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.